Skip to main content

Table 1. Circulatory parameters of the four patients

From: Pitfalls of anesthetic management with the Impella® 5.0 device: a case series

PatientAge (years) /sexBSA (m2)Primary
disease
Preoperative
EF (%)
Preoperative
concomitant VAD
ABP
PAP
CVP
upon arrival in the operating room (after cessation of IABP) (mmHg)
Approach
vessel
Assisted flow rate (L/min-1)CCO
(L/min) and CCI (L/min/m2)
monitored with pulmonary artery catheter
Postoperative
concomitant VAD
Total flow rate*1 (L/min)
Total flow rate/BSA (L/min/m2)
Inotropic agent and vasoconstrictor dose*2 (μg/kg/min)Mixed venous oxygen saturation (%)ABP
PAP
CVP on postoperative day 1 (mmHg)
Duration of Impella 5.0 placement (days)Outcome
158
M
1.7ICM11PCPS
IABP
94/58 (67)
32/19 (35)
7
RSCAP-9
5.0
3.5
2.0
None3.5
2.1
DOA 6
DOB 6
NAD 0.3
65%64/59 (61)
44/26 (28)
5
8Implantable LVAD
243
F
1.5FMC5-10PCPS
IABP
71/66 (66)
28/24 (26)
8
AsAoP-9
4.5
3.1
2.1
PCPS
2.2 L/min
5.3
3.5
DOA 3
DOB 6
86%86/74 (77)
19/11 (14)
10
17Implantable LVAD
354
M
1.8dHCM10-15PCPS
IABP
70/52 (63)
42/28 (31)
12
RSCAP-9
4.8
3.7
2.1
PCPS
2.1 L/min
5.8
3.2
DOA 3
NAD 0.1
70%82/78 (79)
47/24 (33)
12
27Implantable LVAD
  1. ICM ischemic cardiomyopathy, AMI acute myocardial infarction, FMC fulminant myocarditis, dHCM dilated phase of hypertrophic cardiomyopathy, BSA body mass index, PCPS percutaneous cardiopulmonary support, IABP intra-aortic balloon pumping, ECMO extracorporeal membrane oxygenation, ABP arterial blood pressure, PAP pulmonary arterial pressure, CVP central venous pressure, RSCA right subclavian artery, AsAo ascending aorta, CCO continuous cardiac output, CCI continuous cardiac index, AI aortic insufficiency, DOA dopamine, DOB dobutamine, NA noradrenaline
  2. *1Total flow rate is based on the sum of CCO determined with the thermodilution technique using the pulmonary artery catheter and PCPS flow rate
  3. *2Maintenance dose after leaving the operating room